By Product: Ozempic dominates, Tirzepatide products growing fastest Ozempic (semaglutide 0.5mg/1mg/2mg weekly subcutaneous injection) dominated the GLP-1 receptor agonist market with approximately 35.12% market share in 2025, driven by its combination of robust clinical efficacy data, early market entry, broad diabetes label, established prescriber relationships, and expanded off-label use for weight management before Wegovy's commercial scale-up
The complexity of dose regimens, the patients perception of administration, and fear of injections may affect the rate of commencing injectable treatment
Semaglutide, a member of the glucagon-like peptide-1 receptor agonists (GLP-1 agonists) class, has emerged as a game-changer in weight loss management
Visualization and manual inspection of selected overlays and electrostatic maps were performed using VIDA 5.0.4.1
Tambm veremos seus benefcios, riscos, possveis interaes medicamentosas e sinais de alerta que merecem ateno
If appetite suppression diminishes or plateaus, consult your healthcare provider who may adjust your dose within FDA-approved ranges or recommend additional interventions